These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38275509)

  • 21. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy.
    Nakahara J; Maeda M; Aiso S; Suzuki N
    Clin Rev Allergy Immunol; 2012 Feb; 42(1):26-34. PubMed ID: 22189514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Efficacy of Psychological Interventions for Managing Fatigue in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    Phyo AZZ; Demaneuf T; De Livera AM; Jelinek GA; Brown CR; Marck CH; Neate SL; Taylor KL; Mills T; O'Kearney E; Karahalios A; Weiland TJ
    Front Neurol; 2018; 9():149. PubMed ID: 29670565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
    Brañas P; Jordan R; Fry-Smith A; Burls A; Hyde C
    Health Technol Assess; 2000; 4(27):1-61. PubMed ID: 11074395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.
    Pilotto S; Zoledziewska M; Fenu G; Cocco E; Lorefice L
    Mult Scler Relat Disord; 2023 May; 73():104671. PubMed ID: 37001407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis.
    Bross M; Hackett M; Bernitsas E
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-occurrence of Fatigue and Depression in People With Multiple Sclerosis: A Mini-Review.
    Tarasiuk J; Kapica-Topczewska K; Czarnowska A; Chorąży M; Kochanowicz J; Kułakowska A
    Front Neurol; 2021; 12():817256. PubMed ID: 35242093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
    Deeb O; Nabulsi M
    Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart rate variability and fatigue in MS: two parallel pathways representing disseminated inflammatory processes?
    Garis G; Haupts M; Duning T; Hildebrandt H
    Neurol Sci; 2023 Jan; 44(1):83-98. PubMed ID: 36125573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporating patients' preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review.
    Ngorsuraches S; Poudel N
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):183-195. PubMed ID: 33472451
    [No Abstract]   [Full Text] [Related]  

  • 32. Disease modifying therapy management of multiple sclerosis after stem cell therapies: A retrospective case series.
    Manzano GS; Holroyd KB; Kaplan T; Bhattacharyya S; Chitnis T; Hotan G; Zurawski J; Galetta KM; Mateen FJ
    Mult Scler Relat Disord; 2022 Jul; 63():103861. PubMed ID: 35576727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R; Oh J
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
    da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
    BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment.
    Braley TJ; Chervin RD
    Sleep; 2010 Aug; 33(8):1061-7. PubMed ID: 20815187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction in Fatigue Symptoms Following the Administration of Nutritional Supplements in Patients with Multiple Sclerosis.
    Ferorelli P; Antonelli F; Shevchenko A; Mischiati C; Doepp M; Lenzi S; Borromeo I; Feriotto G; Beninati S
    Med Sci (Basel); 2021 Jul; 9(3):. PubMed ID: 34287336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
    Sancho-Saldaña A; Gil-Sánchez A; González-Mingot C; Peralta S; Solana MJ; Torres P; Juanes A; Quibus L; Ruiz E; Sanpedro E; Quirant-Sánchez B; Martínez-Cáceres E; Ramo Tello C; Presas-Rodríguez S; García Rubio S; Baron BP; Ramió-Torrentà L; Sotoca J; González-Suárez I; Eichau S; Prieto-González JM; Blasco Quilez MR; Sabín-Muñoz J; Sánchez-López AJ; Llorens Calatayud G; Calles C; Sempere ÁP; Garcés M; Carmona O; Moral E; Hervás JV; Blanco Y; Sola-Valls N; Tellez Lara N; Forero L; Brieva L
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.